RxDoctor Payments Data

Crystal Rego, DO

Internal Medicine · Miami Beach, FLNPI 1598184996

Payments from drug & device makers

$1,823in general payments, 2019–2025

Across 75 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$286
  • Exact Sciences$205
  • Phathom Pharmaceuticals, Inc.$167
  • GSK$150
  • Merck$125
  • Pfizer$110
  • plus $780 from 19 others

What the payments were for

  • Food & beverage$1,823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,823 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$66,061
Medicare patients
172
Services billed
908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$32,986
XareltoRivaroxaban18$26,170
JanuviaSitagliptin Phosphate12$20,130
RybelsusSemaglutide11$15,452
FarxigaDapagliflozin Propanediol13$10,934
Rosuvastatin Calcium91$1,411
Atorvastatin Calcium147$1,304
SynthroidLevothyroxine Sodium15$1,277
Ventolin HfaAlbuterol Sulfate15$808
Omeprazole42$658
Losartan Potassium92$534
Amlodipine Besylate71$392
Gabapentin22$387
Escitalopram Oxalate21$357
Nifedipine ErNifedipine19$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$286$48,43744 claims
Johnson & JohnsonXarelto$79$26,17018 claims
MerckJanuvia$125$20,13012 claims
AbbVieSynthroid$21$1,27715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →